Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,797
archived clinical trials in
Peripheral Vascular Disease

Evaluation of the GORE TIGRIS Vascular Stent
Evaluation of the GORE TIGRIS Vascular Stent in the Treatment of Atherosclerotic Lesions of the Superficial Femoral and Proximal Popliteal Arteries
Status: Enrolling
Updated:  9/8/2017
Minneapolis Radiology and Vascular
mi
from
Minneapolis, MN
Evaluation of the GORE TIGRIS Vascular Stent
Evaluation of the GORE TIGRIS Vascular Stent in the Treatment of Atherosclerotic Lesions of the Superficial Femoral and Proximal Popliteal Arteries
Status: Enrolling
Updated: 9/8/2017
Minneapolis Radiology and Vascular
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Evaluation of the GORE TIGRIS Vascular Stent
Evaluation of the GORE TIGRIS Vascular Stent in the Treatment of Atherosclerotic Lesions of the Superficial Femoral and Proximal Popliteal Arteries
Status: Enrolling
Updated:  9/8/2017
SSM Health Care
mi
from
Saint Charles, MO
Evaluation of the GORE TIGRIS Vascular Stent
Evaluation of the GORE TIGRIS Vascular Stent in the Treatment of Atherosclerotic Lesions of the Superficial Femoral and Proximal Popliteal Arteries
Status: Enrolling
Updated: 9/8/2017
SSM Health Care
mi
from
Saint Charles, MO
Click here to add this to my saved trials
Evaluation of the GORE TIGRIS Vascular Stent
Evaluation of the GORE TIGRIS Vascular Stent in the Treatment of Atherosclerotic Lesions of the Superficial Femoral and Proximal Popliteal Arteries
Status: Enrolling
Updated:  9/8/2017
Vascular Research Institute
mi
from
Morristown, NJ
Evaluation of the GORE TIGRIS Vascular Stent
Evaluation of the GORE TIGRIS Vascular Stent in the Treatment of Atherosclerotic Lesions of the Superficial Femoral and Proximal Popliteal Arteries
Status: Enrolling
Updated: 9/8/2017
Vascular Research Institute
mi
from
Morristown, NJ
Click here to add this to my saved trials
Evaluation of the GORE TIGRIS Vascular Stent
Evaluation of the GORE TIGRIS Vascular Stent in the Treatment of Atherosclerotic Lesions of the Superficial Femoral and Proximal Popliteal Arteries
Status: Enrolling
Updated:  9/8/2017
Ohio Health Research Institute
mi
from
Columbus, OH
Evaluation of the GORE TIGRIS Vascular Stent
Evaluation of the GORE TIGRIS Vascular Stent in the Treatment of Atherosclerotic Lesions of the Superficial Femoral and Proximal Popliteal Arteries
Status: Enrolling
Updated: 9/8/2017
Ohio Health Research Institute
mi
from
Columbus, OH
Click here to add this to my saved trials
Evaluation of the GORE TIGRIS Vascular Stent
Evaluation of the GORE TIGRIS Vascular Stent in the Treatment of Atherosclerotic Lesions of the Superficial Femoral and Proximal Popliteal Arteries
Status: Enrolling
Updated:  9/8/2017
Providence Heat & Vascular Institute
mi
from
Portland, OR
Evaluation of the GORE TIGRIS Vascular Stent
Evaluation of the GORE TIGRIS Vascular Stent in the Treatment of Atherosclerotic Lesions of the Superficial Femoral and Proximal Popliteal Arteries
Status: Enrolling
Updated: 9/8/2017
Providence Heat & Vascular Institute
mi
from
Portland, OR
Click here to add this to my saved trials
Evaluation of the GORE TIGRIS Vascular Stent
Evaluation of the GORE TIGRIS Vascular Stent in the Treatment of Atherosclerotic Lesions of the Superficial Femoral and Proximal Popliteal Arteries
Status: Enrolling
Updated:  9/8/2017
Heritage Valley Health System
mi
from
Beaver, PA
Evaluation of the GORE TIGRIS Vascular Stent
Evaluation of the GORE TIGRIS Vascular Stent in the Treatment of Atherosclerotic Lesions of the Superficial Femoral and Proximal Popliteal Arteries
Status: Enrolling
Updated: 9/8/2017
Heritage Valley Health System
mi
from
Beaver, PA
Click here to add this to my saved trials
Evaluation of the GORE TIGRIS Vascular Stent
Evaluation of the GORE TIGRIS Vascular Stent in the Treatment of Atherosclerotic Lesions of the Superficial Femoral and Proximal Popliteal Arteries
Status: Enrolling
Updated:  9/8/2017
Univ of Pennsylvania
mi
from
Philadelphia, PA
Evaluation of the GORE TIGRIS Vascular Stent
Evaluation of the GORE TIGRIS Vascular Stent in the Treatment of Atherosclerotic Lesions of the Superficial Femoral and Proximal Popliteal Arteries
Status: Enrolling
Updated: 9/8/2017
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Evaluation of the GORE TIGRIS Vascular Stent
Evaluation of the GORE TIGRIS Vascular Stent in the Treatment of Atherosclerotic Lesions of the Superficial Femoral and Proximal Popliteal Arteries
Status: Enrolling
Updated:  9/8/2017
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Evaluation of the GORE TIGRIS Vascular Stent
Evaluation of the GORE TIGRIS Vascular Stent in the Treatment of Atherosclerotic Lesions of the Superficial Femoral and Proximal Popliteal Arteries
Status: Enrolling
Updated: 9/8/2017
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Evaluation of the GORE TIGRIS Vascular Stent
Evaluation of the GORE TIGRIS Vascular Stent in the Treatment of Atherosclerotic Lesions of the Superficial Femoral and Proximal Popliteal Arteries
Status: Enrolling
Updated:  9/8/2017
Miriam Hospital
mi
from
Providence, RI
Evaluation of the GORE TIGRIS Vascular Stent
Evaluation of the GORE TIGRIS Vascular Stent in the Treatment of Atherosclerotic Lesions of the Superficial Femoral and Proximal Popliteal Arteries
Status: Enrolling
Updated: 9/8/2017
Miriam Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Evaluation of the GORE TIGRIS Vascular Stent
Evaluation of the GORE TIGRIS Vascular Stent in the Treatment of Atherosclerotic Lesions of the Superficial Femoral and Proximal Popliteal Arteries
Status: Enrolling
Updated:  9/8/2017
North Central Heart Institute
mi
from
Sioux Falls, SD
Evaluation of the GORE TIGRIS Vascular Stent
Evaluation of the GORE TIGRIS Vascular Stent in the Treatment of Atherosclerotic Lesions of the Superficial Femoral and Proximal Popliteal Arteries
Status: Enrolling
Updated: 9/8/2017
North Central Heart Institute
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Evaluation of the GORE TIGRIS Vascular Stent
Evaluation of the GORE TIGRIS Vascular Stent in the Treatment of Atherosclerotic Lesions of the Superficial Femoral and Proximal Popliteal Arteries
Status: Enrolling
Updated:  9/8/2017
Baylor Research Institute
mi
from
Dallas, TX
Evaluation of the GORE TIGRIS Vascular Stent
Evaluation of the GORE TIGRIS Vascular Stent in the Treatment of Atherosclerotic Lesions of the Superficial Femoral and Proximal Popliteal Arteries
Status: Enrolling
Updated: 9/8/2017
Baylor Research Institute
mi
from
Dallas, TX
Click here to add this to my saved trials
Evaluation of the GORE TIGRIS Vascular Stent
Evaluation of the GORE TIGRIS Vascular Stent in the Treatment of Atherosclerotic Lesions of the Superficial Femoral and Proximal Popliteal Arteries
Status: Enrolling
Updated:  9/8/2017
Presbyterian Hospital of Dallas
mi
from
Dallas, TX
Evaluation of the GORE TIGRIS Vascular Stent
Evaluation of the GORE TIGRIS Vascular Stent in the Treatment of Atherosclerotic Lesions of the Superficial Femoral and Proximal Popliteal Arteries
Status: Enrolling
Updated: 9/8/2017
Presbyterian Hospital of Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
Evaluation of the GORE TIGRIS Vascular Stent
Evaluation of the GORE TIGRIS Vascular Stent in the Treatment of Atherosclerotic Lesions of the Superficial Femoral and Proximal Popliteal Arteries
Status: Enrolling
Updated:  9/8/2017
CAMC Health Education and Research Institute
mi
from
Charleston, WV
Evaluation of the GORE TIGRIS Vascular Stent
Evaluation of the GORE TIGRIS Vascular Stent in the Treatment of Atherosclerotic Lesions of the Superficial Femoral and Proximal Popliteal Arteries
Status: Enrolling
Updated: 9/8/2017
CAMC Health Education and Research Institute
mi
from
Charleston, WV
Click here to add this to my saved trials
The TRansendocardial Stem Cell Injection Delivery Effects on Neomyogenesis STudy (The TRIDENT Study)
A Phase II, Randomized, Blinded, Study of the Safety and Efficacy of Transendocardial Injection of Allogeneic Human Mesenchymal Stem Cells (hMSCs) (20 Million or 100 Million Total MSCs) in Patients With Chronic Ischemic Left Ventricular Dysfunction Secondary to Myocardial Infarction.
Status: Enrolling
Updated:  9/13/2017
ISCI / University of Miami
mi
from
Miami, FL
The TRansendocardial Stem Cell Injection Delivery Effects on Neomyogenesis STudy (The TRIDENT Study)
A Phase II, Randomized, Blinded, Study of the Safety and Efficacy of Transendocardial Injection of Allogeneic Human Mesenchymal Stem Cells (hMSCs) (20 Million or 100 Million Total MSCs) in Patients With Chronic Ischemic Left Ventricular Dysfunction Secondary to Myocardial Infarction.
Status: Enrolling
Updated: 9/13/2017
ISCI / University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Pharmacokinetics of Single-Dose Oral Ranolazine in Hemodialysis Patients
Pharmacokinetics of Single-Dose Oral Ranolazine in Hemodialysis Patients
Status: Enrolling
Updated:  9/13/2017
University of Michigan Hospital
mi
from
Ann Arbor, MI
Pharmacokinetics of Single-Dose Oral Ranolazine in Hemodialysis Patients
Pharmacokinetics of Single-Dose Oral Ranolazine in Hemodialysis Patients
Status: Enrolling
Updated: 9/13/2017
University of Michigan Hospital
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Study of Hepatocyte Growth Factor (HGF) Via Plasmid Vector to Improve Perfusion in Critical Limb Ischemia Patients With Peripheral Ischemic Ulcers
A Phase II Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety and Efficacy of AMG0001 to Improve Perfusion in Critical Limb Ischemia in Subjects Who Have Peripheral Ischemic Ulcers
Status: Enrolling
Updated:  9/14/2017
Baptist Clinical Research
mi
from
Pensacola, FL
Study of Hepatocyte Growth Factor (HGF) Via Plasmid Vector to Improve Perfusion in Critical Limb Ischemia Patients With Peripheral Ischemic Ulcers
A Phase II Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety and Efficacy of AMG0001 to Improve Perfusion in Critical Limb Ischemia in Subjects Who Have Peripheral Ischemic Ulcers
Status: Enrolling
Updated: 9/14/2017
Baptist Clinical Research
mi
from
Pensacola, FL
Click here to add this to my saved trials
Study of Hepatocyte Growth Factor (HGF) Via Plasmid Vector to Improve Perfusion in Critical Limb Ischemia Patients With Peripheral Ischemic Ulcers
A Phase II Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety and Efficacy of AMG0001 to Improve Perfusion in Critical Limb Ischemia in Subjects Who Have Peripheral Ischemic Ulcers
Status: Enrolling
Updated:  9/14/2017
The Care Group, LLC
mi
from
Indianapolis, IN
Study of Hepatocyte Growth Factor (HGF) Via Plasmid Vector to Improve Perfusion in Critical Limb Ischemia Patients With Peripheral Ischemic Ulcers
A Phase II Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety and Efficacy of AMG0001 to Improve Perfusion in Critical Limb Ischemia in Subjects Who Have Peripheral Ischemic Ulcers
Status: Enrolling
Updated: 9/14/2017
The Care Group, LLC
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study of Hepatocyte Growth Factor (HGF) Via Plasmid Vector to Improve Perfusion in Critical Limb Ischemia Patients With Peripheral Ischemic Ulcers
A Phase II Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety and Efficacy of AMG0001 to Improve Perfusion in Critical Limb Ischemia in Subjects Who Have Peripheral Ischemic Ulcers
Status: Enrolling
Updated:  9/14/2017
Boston Med Ctr
mi
from
Boston, MA
Study of Hepatocyte Growth Factor (HGF) Via Plasmid Vector to Improve Perfusion in Critical Limb Ischemia Patients With Peripheral Ischemic Ulcers
A Phase II Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety and Efficacy of AMG0001 to Improve Perfusion in Critical Limb Ischemia in Subjects Who Have Peripheral Ischemic Ulcers
Status: Enrolling
Updated: 9/14/2017
Boston Med Ctr
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Hepatocyte Growth Factor (HGF) Via Plasmid Vector to Improve Perfusion in Critical Limb Ischemia Patients With Peripheral Ischemic Ulcers
A Phase II Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety and Efficacy of AMG0001 to Improve Perfusion in Critical Limb Ischemia in Subjects Who Have Peripheral Ischemic Ulcers
Status: Enrolling
Updated:  9/14/2017
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Study of Hepatocyte Growth Factor (HGF) Via Plasmid Vector to Improve Perfusion in Critical Limb Ischemia Patients With Peripheral Ischemic Ulcers
A Phase II Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety and Efficacy of AMG0001 to Improve Perfusion in Critical Limb Ischemia in Subjects Who Have Peripheral Ischemic Ulcers
Status: Enrolling
Updated: 9/14/2017
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated:  9/17/2017
University of Alabama at Birmingham School of Medicine
mi
from
Birmingham, AL
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated: 9/17/2017
University of Alabama at Birmingham School of Medicine
mi
from
Birmingham, AL
Click here to add this to my saved trials
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated:  9/17/2017
Banner Good Samaritan Transplant
mi
from
Phoenix, AZ
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated: 9/17/2017
Banner Good Samaritan Transplant
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated:  9/17/2017
Cedars-Sinai Health System/Center for Kidney Diseases and Transplantation
mi
from
Los Angeles, CA
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated: 9/17/2017
Cedars-Sinai Health System/Center for Kidney Diseases and Transplantation
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated:  9/17/2017
University of California at Los Angeles
mi
from
Los Angeles, CA
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated: 9/17/2017
University of California at Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated:  9/17/2017
University of California at San Francisco
mi
from
San Francisco, CA
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated: 9/17/2017
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated:  9/17/2017
Northwestern University
mi
from
Chicago, IL
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated: 9/17/2017
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated:  9/17/2017
Southern Illinois University
mi
from
Springfield, IL
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated: 9/17/2017
Southern Illinois University
mi
from
Springfield, IL
Click here to add this to my saved trials
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated:  9/17/2017
Indiana University
mi
from
Indianapolis, IN
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated: 9/17/2017
Indiana University
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated:  9/17/2017
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated: 9/17/2017
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Click here to add this to my saved trials
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated:  9/17/2017
Maine Medical Center
mi
from
Portland, ME
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated: 9/17/2017
Maine Medical Center
mi
from
Portland, ME
Click here to add this to my saved trials
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated:  9/17/2017
University of Maryland Medical Center
mi
from
Baltimore, MD
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated: 9/17/2017
University of Maryland Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated:  9/17/2017
Brigham and Women's Hosp
mi
from
Boston, MA
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated: 9/17/2017
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated:  9/17/2017
University of Michigan Medical Center
mi
from
Ann Arbor, MI
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated: 9/17/2017
University of Michigan Medical Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated:  9/17/2017
Hennepin County Medical Center
mi
from
Minneapolis, MN
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated: 9/17/2017
Hennepin County Medical Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated:  9/17/2017
Faireview University Medical Center
mi
from
Minneapolis, MN
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated: 9/17/2017
Faireview University Medical Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated:  9/17/2017
The Mayo Clinic
mi
from
Rochester, MN
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated: 9/17/2017
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated:  9/17/2017
Albany Medical Center
mi
from
Albany, NY
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated: 9/17/2017
Albany Medical Center
mi
from
Albany, NY
Click here to add this to my saved trials
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated:  9/17/2017
State University of New York - Downstate Medical Center
mi
from
Brooklyn, NY
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated: 9/17/2017
State University of New York - Downstate Medical Center
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated:  9/17/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated: 9/17/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated:  9/17/2017
East Carolina University
mi
from
Greenville, NC
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated: 9/17/2017
East Carolina University
mi
from
Greenville, NC
Click here to add this to my saved trials
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated:  9/17/2017
Ohio State University Medical Center
mi
from
Columbus, OH
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated: 9/17/2017
Ohio State University Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated:  9/17/2017
Oregon Health and Sciences University
mi
from
Portland, OR
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated: 9/17/2017
Oregon Health and Sciences University
mi
from
Portland, OR
Click here to add this to my saved trials
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated:  9/17/2017
Drexel University
mi
from
Philadelphia, PA
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated: 9/17/2017
Drexel University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated:  9/17/2017
Rhode Island Hospital
mi
from
Providence, RI
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated: 9/17/2017
Rhode Island Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated:  9/17/2017
University of Wisconsin-Madison
mi
from
Madison, WI
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated: 9/17/2017
University of Wisconsin-Madison
mi
from
Madison, WI
Click here to add this to my saved trials
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated:  9/17/2017
Medical College of Wisconsin
mi
from
Milwaukee, WI
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated: 9/17/2017
Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated:  9/17/2017
Universidade Federal de Sao Paulo
mi
from
Sao Paulo,
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated: 9/17/2017
Universidade Federal de Sao Paulo
mi
from
Sao Paulo,
Click here to add this to my saved trials
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated:  9/17/2017
Washington University
mi
from
Saint Louis, MO
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated: 9/17/2017
Washington University
mi
from
Saint Louis, MO
Click here to add this to my saved trials
3 Month PHI PAD PoM Study
A Multi-center, Placebo-controlled Study to Evaluate the Safety and Efficacy of GSK1278863 vs. Placebo in Subjects With Peripheral Artery Disease (PAD).
Status: Enrolling
Updated:  9/20/2017
GSK Investigational Site
mi
from
Palo Alto, CA
3 Month PHI PAD PoM Study
A Multi-center, Placebo-controlled Study to Evaluate the Safety and Efficacy of GSK1278863 vs. Placebo in Subjects With Peripheral Artery Disease (PAD).
Status: Enrolling
Updated: 9/20/2017
GSK Investigational Site
mi
from
Palo Alto, CA
Click here to add this to my saved trials
3 Month PHI PAD PoM Study
A Multi-center, Placebo-controlled Study to Evaluate the Safety and Efficacy of GSK1278863 vs. Placebo in Subjects With Peripheral Artery Disease (PAD).
Status: Enrolling
Updated:  9/20/2017
GSK Investigational Site
mi
from
Vista, CA
3 Month PHI PAD PoM Study
A Multi-center, Placebo-controlled Study to Evaluate the Safety and Efficacy of GSK1278863 vs. Placebo in Subjects With Peripheral Artery Disease (PAD).
Status: Enrolling
Updated: 9/20/2017
GSK Investigational Site
mi
from
Vista, CA
Click here to add this to my saved trials
3 Month PHI PAD PoM Study
A Multi-center, Placebo-controlled Study to Evaluate the Safety and Efficacy of GSK1278863 vs. Placebo in Subjects With Peripheral Artery Disease (PAD).
Status: Enrolling
Updated:  9/20/2017
GSK Investigational Site
mi
from
Clearwater, FL
3 Month PHI PAD PoM Study
A Multi-center, Placebo-controlled Study to Evaluate the Safety and Efficacy of GSK1278863 vs. Placebo in Subjects With Peripheral Artery Disease (PAD).
Status: Enrolling
Updated: 9/20/2017
GSK Investigational Site
mi
from
Clearwater, FL
Click here to add this to my saved trials